EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework

Yingping Chen, Yinchu Song, Yiwen Xie, Jianyi Pan

Biochemical Pharmacology · 2026-06 · 248 · 117846

DOI: 10.1016/j.bcp.2026.117846 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-06. Verfasst von Yingping Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences…. Hauptthemen laut MEDLINE: Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 186 Literaturangaben. Gefördert von: Basic Public Welfare Research Program of Zhejiang Province, Zhejiang Sci-Tech University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic proteins are central to modern pharmacotherapy, yet their clinical utility is often constrained by short plasma half-life and immunogenicity. Six major half-life extension platforms-PEGylation, hydrophilic polypeptide (XTEN/PAS) fusion, glycoengineering, Fc domain-based strategies, human serum albumin (HSA)-centered approaches, and lipidation-have yielded numerous clinically approved therapeutics, yet are typically reviewed in isolation. This review presents a systematic, mechanism-driven comparison of these platforms, evaluating their effects on pharmacokinetics, tissue distribution, immunogenicity, conformational stability, and manufacturability. We highlight key molecular principles, representative clinical candidates, and emerging hybrid designs. Based on this synthesis, we propose a decision framework that aligns platform selection with therapeutic indication, modality, and development constraints. Finally, we discuss unresolved challenges-including accurate immunogenicity prediction and regulatory harmonization-that must be addressed to fully realize safer, longer-acting biologics. This review equips pharmacologists and biotherapeutic developers with an evidence-based, cross-platform toolkit to rationally design and select next-generation long-acting protein therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteinsHumansHalf-LifeAnimalsProtein Engineering

Stichwörter der Autor:innen

FcRn-mediated recyclingHalf-life extensionImmunogenicity mitigationPharmacokinetic (PK) optimizationProtein modificationTherapeuticproteins engineering

Substanzen

Proteins

Autor:innen und Institutionen

  • Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
  • Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China. E…

Förderung

  • Basic Public Welfare Research Program of Zhejiang Province
  • Zhejiang Sci-Tech University
  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Song, Y., Xie, Y., & Pan, J. (2026). Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework. Biochemical Pharmacology, 248, 117846. https://doi.org/10.1016/j.bcp.2026.117846

Vancouver

Chen Y, Song Y, Xie Y, Pan J. Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework. Biochemical Pharmacology. 2026;248:117846. doi:10.1016/j.bcp.2026.117846

BibTeX
@article{Chen2026,
  author = {Chen, Yingping and Song, Yinchu and Xie, Yiwen and Pan, Jianyi},
  title = {Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {248},
  pages = {117846},
  doi = {10.1016/j.bcp.2026.117846}
}
Kostenlos starten →